NASDAQ:RVNC

Revance Therapeutics - RVNC Stock Forecast, Price & News

$29.06

+0.83 (+2.94%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $28.20
▼
$29.12
50-Day Range: $15.52
▼
$29.06
52-Week Range: $11.27
▼
$29.51

Volume: 1.66 million shs
Average Volume: 908,724 shs
Market Capitalization: $2.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.00

Revance Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 34.2% Upside
$39.00 Price Target
Short Interest: Bearish
11.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 0.87
Based on 4 Articles This Week
Insider Trading: Selling Shares
$297,770 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.69) to ($3.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

145th out of 1,087 stocks

Pharmaceutical Preparations Industry

55th out of 546 stocks

4.4

Analyst's Opinion

Consensus Rating
Revance Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.00, Revance Therapeutics has a forecasted upside of 34.2% from its current price of $29.06.
Amount of Analyst Coverage
Revance Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.79% of the float of Revance Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Revance Therapeutics has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Revance Therapeutics has recently increased by 3.74%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Revance Therapeutics does not currently pay a dividend.
Dividend Growth
Revance Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revance Therapeutics is -0.88.

2.7

News and Social Media Coverage

News Sentiment
Revance Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Revance Therapeutics this week, compared to 4 articles on an average week.
Search Interest
21 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 163% compared to the previous 30 days.
MarketBeat Follows
18 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 260% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $297,770.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Revance Therapeutics is held by insiders.
Percentage Held by Institutions
77.08% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revance Therapeutics are expected to grow in the coming year, from ($3.69) to ($3.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revance Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revance Therapeutics is -7.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revance Therapeutics has a P/B Ratio of 30.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revance Therapeutics (NASDAQ:RVNC) Stock

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Stock News Headlines

October 3, 2022 | marketbeat.com

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers (RVNC)

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

October 4, 2022 | americanbankingnews.com

Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of "Moderate Buy" from Analysts

September 21, 2022 | finance.yahoo.com

Revance to Participate in the Guggenheim Nantucket Therapeutics Conference

September 19, 2022 | finance.yahoo.com

Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal

September 17, 2022 | finance.yahoo.com

Revance Therapeutics' (NASDAQ:RVNC) investors will be pleased with their respectable 80% return over the last three years

September 15, 2022 | finance.yahoo.com

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

September 15, 2022 | finance.yahoo.com

Revance to Present Data from Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY™ (DaxibotulinumtoxinA-lanm) Injection for the Treatment of Upper Limb Spasticity at the International Congress of Parkinson and Movement Disorder Society (MDS)

September 13, 2022 | nasdaq.com

Revance Therapeutics Prices Upsized Underwritten Public Offering Of 8 Mln Shares At $25.00/shr

September 13, 2022 | finance.yahoo.com

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

September 12, 2022 | finance.yahoo.com

Revance Announces Proposed Public Offering of Common Stock

September 9, 2022 | msn.com

A Longer-Acting Botox Competitor is Coming

September 9, 2022 | finance.yahoo.com

There's a New Way to Get Rid of Wrinkles

September 9, 2022 | finance.yahoo.com

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

September 9, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Revance Therapeutics

September 9, 2022 | markets.businessinsider.com

Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know

September 8, 2022 | finance.yahoo.com

Botox rival can be 'more broadly used' in therapeutics: Revance CEO

September 8, 2022 | msn.com

Revance Shares Jump 18% After FDA Approves Botox Rival Daxxify

September 8, 2022 | nasdaq.com

U.S. FDA approves Revance's wrinkle treatment

September 8, 2022 | markets.businessinsider.com

Revance Therapeutics Announces FDA Approval Of DAXXIFY - Quick Facts

September 8, 2022 | markets.businessinsider.com

Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines

September 8, 2022 | seekingalpha.com

Revance climbs 14% as FDA approves facial injectable for frown lines

September 8, 2022 | finance.yahoo.com

FDA Approves New Botox Competitor From Revance Therapeutics

September 8, 2022 | finance.yahoo.com

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

September 8, 2022 | finance.yahoo.com

FDA Approves New Botox Rival

September 7, 2022 | nasdaq.com

Noteworthy Wednesday Option Activity: CMG, RVNC, GFF

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RVNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RVNC Company Calendar

Last Earnings: 8/09/2022
Today: 10/04/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVNC
CUSIP: N/A
CIK: 1479290
Web: www.revance.com
Phone: (615) 724-7755
Fax: 510-742-3401
Employees: 495
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $39.00
High Stock Price Forecast: $65.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +34.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-281,310,000.00
Net Margins: -265.04%
Pretax Margin: -265.04%
Return on Equity: -497.77%
Return on Assets: -45.50%

Debt

Debt-to-Equity Ratio: 14.80
Current Ratio: 3.38
Quick Ratio: 3.20

Sales & Book Value

Annual Sales: $77.80 million
Price / Sales: 27.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 30.59

Miscellaneous

Outstanding Shares: 73,106,000
Free Float: 69,378,000
Market Cap: $2.12 billion
Optionable: Optionable
Beta: 0.64

Key Executives

Mr. Mark J. Foley (Age 57)
CEO & Director
Comp: $1.4M

Mr. Dustin S. Sjuts (Age 43)
Pres
Comp: $829.22k

Mr. Tobin C. Schilke (Age 47)
CFO & Principal Accounting Officer
Comp: $633.61k

Mr. Aubrey Rankin (Age 46)
Consultant
Comp: $881.24k

Jessica Serra
Head of Investor Relations & ESG

Mr. Dwight Moxie (Age 45)
Sr. VP, Gen. Counsel & Corp. Sec.

Ms. Jeanie D. Herbert
Sr. Director of Investor Relations & Corp. Communications

Ms. Taryn Conway
VP of Marketing

Mr. Justin Ford
Sr. VP of HR & Head of People

Ms. Azita Nejad
Sr. VP of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVNC Stock - Frequently Asked Questions

Should I buy or sell Revance Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVNC shares.
View RVNC analyst ratings or view top-rated stocks.
What is Revance Therapeutics' stock price forecast for 2022?: 6 Wall Street research analysts have issued twelve-month price targets for Revance Therapeutics' stock. Their RVNC share price forecasts range from $24.00 to $65.00. On average, they predict the company's share price to reach $39.00 in the next year. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts.
How have RVNC shares performed in 2022?: Revance Therapeutics' stock was trading at $16.32 at the beginning of 2022. Since then, RVNC shares have increased by 78.1% and is now trading at $29.06.
View the best growth stocks for 2022 here.
When is Revance Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our RVNC earnings forecast.
How were Revance Therapeutics' earnings last quarter?: Revance Therapeutics, Inc. (NASDAQ:RVNC) released its quarterly earnings data on Tuesday, August, 9th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.91) by $0.03. The biopharmaceutical company earned $28.37 million during the quarter, compared to analysts' expectations of $27.64 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 497.77% and a negative net margin of 265.04%.
What is Mark Foley's approval rating as Revance Therapeutics' CEO?: 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Revance Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).
What is Revance Therapeutics' stock symbol?: Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How do I buy shares of Revance Therapeutics?: Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Revance Therapeutics' stock price today?: One share of RVNC stock can currently be purchased for approximately $29.06.
How much money does Revance Therapeutics make?: Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.12 billion and generates $77.80 million in revenue each year. The biopharmaceutical company earns $-281,310,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.
How many employees does Revance Therapeutics have?: The company employs 495 workers across the globe.
How can I contact Revance Therapeutics?: Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401.

This page (NASDAQ:RVNC) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Revance Therapeutics - RVNC Stock Forecast, Price & News

Revance Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Revance Therapeutics (NASDAQ:RVNC) Stock

RVNC Stock News Headlines

RVNC Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RVNC Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™